Literature DB >> 2167741

Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.

B Fabris1, H Yamada, R Cubela, B Jackson, F A Mendelsohn, C I Johnston.   

Abstract

1. Angiotensin converting enzyme (ACE) from the rat heart and lung was studied by use of the radioligand [125I]-351A. 2. Displacement of the bound radioinhibitor [125I]-351A was used to assess the relative potency of six ACE inhibitors in rat heart and lung homogenates and estimate the binding association constant (KA). 3. The KA for atrial preparations was significantly higher than that of the lung (P less than 0.025) and also the ventricles (P less than 0.005). Ventricular preparations and preparations from the lung also differed significantly (P less than 0.05). These differences in KA were noted for all six ACE inhibitors used to displace the radioligand. 4. The rank order of potency of the ACE inhibitors was quinaprilat = benazeprilat greater than perindoprilat greater than 351A greater than lisinopril greater than fosinoprilat. 5. Cardiac ACE inhibition was studied ex vivo following oral administration of quinapril to rats. Following 0.3 mg kg-1 quinapril, the time course and degree of inhibition of ventricular and atrial ACE were similar. 6. These results suggest that the detected differences in KA noted have only a limited potential biological significance. The difference in KA may reflect variations in the structure or conformation of ACE in different tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167741      PMCID: PMC1917808          DOI: 10.1111/j.1476-5381.1990.tb15862.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Immunochemical comparison of angiotensin 1 converting enzymes from different rat organs.

Authors:  R Polsky-Cynkin; B L Fanburg
Journal:  Int J Biochem       Date:  1979

2.  Effects of captopril on survival in patients with heart failure.

Authors:  T J Newman; C S Maskin; L G Dennick; J H Meyer; B G Hallows; W H Cooper
Journal:  Am J Med       Date:  1988-03-11       Impact factor: 4.965

3.  Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.

Authors:  W H van Gilst; P A de Graeff; H Wesseling; C D de Langen
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

4.  Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.

Authors:  N Sharpe; J Murphy; H Smith; S Hannan
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

5.  Brain angiotensin: on the way to becoming a well-studied neuropeptide system.

Authors:  D Ganten; R E Lang; E Lehmann; T Unger
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

6.  The NH2- and COOH-terminal sequences of the angiotensin-converting enzyme isozymes from rabbit lung and testis.

Authors:  K Iwata; C Y Lai; H A El-Dorry; R L Soffer
Journal:  Biochem Biophys Res Commun       Date:  1982-08       Impact factor: 3.575

7.  Comparison of angiotensin converting enzyme inhibitors captopril and MK421-diacid in guinea pig atria.

Authors:  A Nakashima; J A Angus; C I Johnston
Journal:  Eur J Pharmacol       Date:  1982-07-16       Impact factor: 4.432

8.  Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide.

Authors:  J N Sharma; P G Fernandez; B K Kim; H Idikio; C R Triggle
Journal:  J Hypertens       Date:  1983-10       Impact factor: 4.844

9.  Interactions between coronary occlusion and the renin-angiotensin system in the dog.

Authors:  G Ertl; R W Alexander; R A Kloner
Journal:  Basic Res Cardiol       Date:  1983 Sep-Oct       Impact factor: 17.165

10.  Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

View more
  7 in total

Review 1.  The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 2.  Fosinopril. Clinical pharmacokinetics and clinical potential.

Authors:  H Shionoiri; M Naruse; K Minamisawa; S Ueda; H Himeno; S Hiroto; I Takasaki
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

3.  The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.

Authors:  M Texter; R S Lees; B Pitt; R E Dinsmore; A C Uprichard
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

Review 4.  Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?

Authors:  Anu Lala; Mary Ann McLaughlin
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

Review 5.  Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

6.  ACE phenotyping in human heart.

Authors:  Victoria E Tikhomirova; Olga A Kost; Olga V Kryukova; Elena Z Golukhova; Naida I Bulaeva; Aigerim Z Zholbaeva; Leo A Bokeria; Joe G N Garcia; Sergei M Danilov
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

7.  Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice.

Authors:  Sameh Saber; Amr Mahmoud; Noha Helal; Eman El-Ahwany; Rasha Abdelghany
Journal:  Open Access Maced J Med Sci       Date:  2018-06-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.